Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WTYX10003
- Development stage
- Preclinical
- Lead developer
- Xiamen Innovax Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
WTYX10003 is an investigational vaccine being developed by Xiamen Innovax Biotech (Sino-Innovax Biotech) for the prevention of hand, foot, and mouth disease (HFMD), herpangina, and other related enterovirus diseases. The vaccine is designed to target enteroviruses, which are common pathogens responsible for these childhood infections. As of 2026, WTYX10003 is in the Clinical Trial Application (CTA) preparation phase, moving towards clinical evaluation.
02
Targets
Enterovirus capsid protein
Beyond the preview
Go deeper on WTYX10003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WTYX10003.